Compound Evidence File
#EC-2026-0807
4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3
Filed under Raw Materials. The bureau holds 109 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
40 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 10.0 | 10.0 | 8 Nov 2025 | 13 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Feb 2026 | 9 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 23 Apr 2026 | 16 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Apr 2026 | 15 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 10.0 | 9.9 | 10.0 | 7 May 2026 | 19 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Apr 2026 | 6 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Nov 2025 | 20 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 19 May 2026 | 20 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Jan 2026 | 28 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 7 May 2026 | 6 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Mar 2026 | 3 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Dec 2025 | 2 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 9.9 | 17 Nov 2025 | 5 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 26 Jun 2026 | 2 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Jun 2026 | 10 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Mar 2026 | 12 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Mar 2026 | 7 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Dec 2025 | 4 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 25 Feb 2026 | 13 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Jun 2026 | 17 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Jul 2026 | 19 Aug 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 9.6 | 9.6 | 9.6 | 13 Feb 2025 | 13 Feb 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 9.2 | 8.9 | 9.5 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.8 | 7.7 | 10.0 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.7 | 8.0 | 9.5 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.3 | 7.6 | 9.0 | 25 May 2026 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.0 | 6.3 | 9.8 | 24 May 2026 | 24 May 2026 |
| InjectifyCASE #VI-2026-0387 | X | 1 | 7.9 | 7.9 | 7.9 | 11 Jun 2025 | 11 Jun 2025 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 1 | 7.7 | 7.7 | 7.7 | 3 Jun 2025 | 3 Jun 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 7.1 | 7.1 | 7.1 | 16 Mar 2025 | 16 Mar 2025 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 6.4 | 6.4 | 6.4 | 21 May 2025 | 21 May 2025 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.0 | 5.4 | 6.5 | 17 Dec 2024 | 17 May 2026 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 5.8 | 4.1 | 7.4 | 2 Apr 2025 | 26 Jan 2026 |
| DeuschemCASE #VI-2026-0004 | X | 1 | 4.3 | 4.3 | 4.3 | 2 Jul 2025 | 2 Jul 2025 |
| Peptides For SaleCASE #VI-2026-0614 | X | 2 | 3.9 | 3.6 | 4.2 | 14 Jan 2025 | 21 May 2026 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 3.9 | 3.9 | 3.9 | 21 May 2025 | 21 May 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 3 | 3.8 | 1.9 | 7.2 | 3 Jul 2025 | 23 May 2026 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
Open any subject to view the batch-level evidence for 4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3 alone.